The study by Pfeffer et al. (2015) focused on the use of Lixisenatide in patients with type 2 diabetes and acute coronary syndrome, while Marso et al. (2016) explored the effects of Liraglutide on cardiovascular outcomes in type 2 diabetes patients. Similarly, Marso et al. (2016) investigated Semaglutide and its impacts on cardiovascular outcomes in patients with type 2 diabetes. Husain et al. (2019) delved into the effects of Oral Semaglutide on cardiovascular outcomes in type 2 diabetes patients. Holman et al. (2017) studied the effects of once-weekly Exenatide on cardiovascular outcomes in type 2 diabetes patients. Hernandez et al. (2018) conducted a study on Albiglutide and its cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease.
Moreover, Gerstein et al.’s research in 2019 examined Dulaglutide and its cardiovascular outcomes in type 2 diabetes patients, while Gerstein et al. (2021) focused on the cardiovascular and renal outcomes with Efpeglenatide in type 2 diabetes. Perkovic et al. (2024) investigated the effects of Semaglutide on chronic kidney disease in patients with type 2 diabetes. Kosiborod et al. (2023) studied Semaglutide in patients with heart failure with preserved ejection fraction and obesity. Gerstein et al. (2019) explored the effects of Dulaglutide on renal outcomes in type 2 diabetes.
Furthermore, Mann et al. (2017) researched Liraglutide and its renal outcomes in type 2 diabetes. Muskiet et al. (2018) investigated Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome. Tuttle et al. (2018) compared Dulaglutide versus Insulin Glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease. Wilding et al. (2021) studied once-weekly Semaglutide in adults with overweight or obesity, while Jastreboff et al. (2022) explored Tirzepatide once weekly for the treatment of obesity. Additionally, Kelly et al. (2020) conducted a randomized controlled trial of Liraglutide for adolescents with obesity, while Wharton et al. (2023) investigated daily oral GLP-1 receptor agonist orforglipron for adults with obesity.
Overall, the research on GLP-1 receptor agonists presents promising results in various aspects of diabetes, cardiovascular health, kidney disease, and obesity management. These studies provide valuable insights into the potential benefits and applications of GLP-1 receptor agonists in treating a range of conditions beyond their traditional use.